News | April 06, 2009

Peer Review Papers Examine SenoRx’s Contura MLB

April 6, 2009 - SenoRx said that two peer-reviewed journal articles summarizing clinical findings related to its Contura Multi-Lumen Balloon (MLB) Catheter are pending publication.

These and other studies support the company’s belief that a patient treated with Contura MLB receives a more targeted dose of radiation, while minimizing radiation to healthy tissue such as
the skin and ribs. As a result, more patients are being treated with Contura MLB who previously were not candidates for accelerated partial breast radiation therapy. One article was published in Brachytherapy and a second has been accepted for publication in The American Surgeon:

"Initial Radiation Experience Evaluating Early Tolerance and Toxicities in Patients Undergoing Accelerated Partial Breast Irradiation Using the Contura Multi-Lumen Balloon (MLB) Breast Brachytherapy Catheter. The authors were Brown, S.; McLaughlin, M.; Pope. K.; Haile, K.; Whitaker T.; Hughes, L.; and Israel, P. -- presented at San Antonio Breast Cancer Symposium (SABCS), December 2008, and in press in Brachytherapy, February 2009.

"Initial Surgical Experience Evaluating Early Tolerance and Toxicities in Patients Undergoing Accelerated Partial Breast Irradiation Using the Contura Multi-Lumen Balloon (MLB) Breast Brachytherapy Catheter.” The authors were : Israel, P.; Robbins, A.; Shroff, P.; Haile, K.; and Pope, K. -- presented at Society of Surgical Oncology (SSO), March 2009, and accepted for publication in The American Surgeon.

Since the beginning of 2009, six additional abstracts have been or are scheduled for presentation at major industry meeting.

For more information: www.senorx.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...